Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists

Yu B. Lishmanov, D. L. Stakheev, A. V. Krylatov, N. V. Naryzhnaya, L. N. Maslov, M. V. Ovchinnikov, F. Kolar

Research output: Contribution to journalArticle

2 Citations (Scopus)


Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide κ-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.

Original languageEnglish
Pages (from-to)696-699
Number of pages4
JournalBulletin of Experimental Biology and Medicine
Issue number6
Publication statusPublished - 19 Nov 2008



  • Chronic treatment with opioid receptor agonists
  • Ischemia
  • Myocardium
  • Reperfusion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this